A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
about
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureImpulsive and compulsive behaviors in Parkinson's diseaseThe use of rotigotine in the treatment of restless legs syndromeRotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.Opposing aging-related shift of excitatory dopamine D1 and inhibitory D3 receptor protein expression in striatum and spinal cordRotigotine for the treatment of Parkinson's disease.Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.Role of dopamine agonists in Parkinson's disease: an update.Rotigotine transdermal system: a short review.Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.Rotigotine transdermal delivery for the treatment of restless legs syndrome.How should we treat a patient with early Parkinson's disease?Pathological gambling in Parkinson's disease--a review of the literature.Rotigotine transdermal patch for the treatment of Parkinson's Disease.Drug safety evaluation of rotigotine.Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.Parkinson's disease: genetics and beyond.No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa.Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease.Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.Identification of the Human SULT Enzymes Involved in the Metabolism of Rotigotine.
P2860
Q33917283-C31618EA-F423-4FD5-A5AD-B0690E004ADCQ34342432-FA09640C-44C5-4ED6-A355-035D5C47E6BDQ34409491-6596EA03-BBFE-4B56-A742-78944AE138ABQ34921068-11FB93D3-A2F8-45F3-AC7B-30FB22645279Q36124394-7816797B-ACD3-4D61-BB0F-CA9F2B9ECFDBQ36466181-78FBF8E0-7889-426D-9168-9B9620EDACAFQ36598111-7B45ACE8-9F65-4B37-B43C-5633D8FBBACEQ36607314-BBE28C12-73A0-4547-9413-5729789EA8E2Q36703436-A6789FB0-4381-402B-A009-C54CA1CB01DBQ36750148-726C44C9-5E38-4913-AEEC-76FF12030C0AQ36847306-6169BD29-07F2-4B7C-8D33-2347728B1302Q36941752-FACE0F26-6355-4A54-9BAF-E4DE717E5ACAQ36972701-512BE682-4125-4264-9041-4FCCF5F86DE5Q37166126-AB035B6C-8773-433D-933E-4DD63FB8CFF8Q37397793-CCD7602E-7266-4AC2-B4DF-3C63E6AE6D5CQ37506391-106CC327-CE45-4871-BFAE-3296899A384EQ37693940-9AA6B93A-8106-4404-8539-66C9B9B535FAQ37775098-DFBF3548-843B-4BD6-8CC7-811FBC555306Q37887679-FA304062-0C12-4123-82D8-17A7532CA6F7Q37982789-C7C63D66-2D00-49E2-8490-602910999322Q37999056-720A0554-89B1-4238-BCE1-274CC1B2E3FAQ38091388-FC45FC89-C89F-4B28-94F6-11E99D8876DDQ38242043-3C165819-C12A-4596-A7D7-5409787566CFQ39416222-C8BB79B4-73CE-40FE-AD8F-9155017581ECQ39810172-738E2EBF-AC41-4086-995B-D12DF9562CEEQ41455787-D278EA72-68A6-4B5F-BED1-4B8DC651E3EFQ41620763-73CEF5A4-397F-4568-8D11-7A611EA5309BQ42628598-028AAB8B-6BBC-4895-BA64-A5BE4DB5CBE2Q43144417-8D26DF78-B8B2-4C43-97E0-D1DB4C97256DQ43976027-19D96C2A-A242-49A4-B7BC-8A558493777BQ45086483-C1F41955-919B-4E89-8D27-CE8F60229CFAQ46952182-02C37045-F973-4E62-910A-FCBD9EC39DE5Q48537131-28AF1117-1EE1-4A14-874C-0900937C4955Q52147949-E6F39E3D-D723-43E4-BDF8-B0A8D9E72566
P2860
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@ast
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@en
type
label
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@ast
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@en
prefLabel
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@ast
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@en
P1433
P1476
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
@en
P2093
Peter Jenner
P356
10.1212/WNL.65.2_SUPPL_1.S3
P407
P433
P577
2005-07-01T00:00:00Z